Get the Stockscreener App
1.76
4.14%
0.07
After Hours:
1.80
0.04
+2.27%
Alector Inc stock is traded at $1.76, with a volume of 1.26M.
It is up +4.14% in the last 24 hours and up +44.26% over the past month.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
See More
Previous Close:
$1.69
Open:
$1.71
24h Volume:
1.26M
Relative Volume:
0.48
Market Cap:
$192.11M
Revenue:
$100.56M
Net Income/Loss:
$-119.05M
P/E Ratio:
-1.4309
EPS:
-1.23
Net Cash Flow:
$-231.16M
1W Performance:
+12.82%
1M Performance:
+44.26%
6M Performance:
+22.22%
1Y Performance:
-11.11%
1-Day Range:
$1.685
$1.765
1-Week Range:
$1.50
$1.765
52-Week Range:
$0.87
$3.3999
Alector Inc Stock (ALEC) Company Profile
Name
Alector Inc
Sector
Industry
Phone
415-231-5660
Address
131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO
Compare ALEC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALEC
Alector Inc
|
1.76 | 184.47M | 100.56M | -119.05M | -231.16M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alector Inc Stock (ALEC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-22-25 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-22-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-22-25 | Downgrade | Mizuho | Outperform → Neutral |
| Oct-22-25 | Downgrade | TD Cowen | Buy → Hold |
| Oct-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-28-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-17-24 | Downgrade | Mizuho | Outperform → Neutral |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-04-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-29-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-26-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-14-23 | Upgrade | Stifel | Hold → Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Sep-25-23 | Initiated | Goldman | Sell |
| Sep-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-13-22 | Initiated | Goldman | Sell |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Sep-27-21 | Initiated | William Blair | Outperform |
| Jan-15-21 | Resumed | BofA Securities | Buy |
| Jun-24-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Goldman | Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-19-20 | Initiated | Stifel | Buy |
| Nov-21-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | Barclays | Overweight |
| Mar-04-19 | Initiated | BofA/Merrill | Buy |
| Mar-04-19 | Initiated | Morgan Stanley | Overweight |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
View All
Alector Inc Stock (ALEC) Latest News
Alector : January 2026 Corporate Presentation - MarketScreener
Alector, Inc. (ALEC) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Setup Watch: Will Sound Group Inc Depositary Receipt stock see PE expansion2025 Technical Patterns & Smart Allocation Stock Tips - moha.gov.vn
What insider trading reveals about Alector Inc. stockMerger & Acquisition Updates & Low Entry Cost Investment - bollywoodhelpline.com
ALEC ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Alector, Inc. - ACCESS Newswire
Alector, Inc. (NASDAQ:ALEC) Given Average Rating of "Reduce" by Analysts - MarketBeat
Investors who lost money on Alector, Inc. should contact Levi & Korsinsky about an ongoing investigationALEC - ACCESS Newswire
Short Interest in Alector, Inc. (NASDAQ:ALEC) Expands By 35.9% - MarketBeat
Alector (NASDAQ:ALEC) Trading 4.8% HigherHere's Why - MarketBeat
Alector, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsALEC - ACCESS Newswire
Shareholder Rights Advocates at Levi & Korsinsky Investigate Alector, Inc. (ALEC) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Is Alector Inc a good long term investmentInterest Rate Changes & Affordable Trading Techniques - earlytimes.in
Alector, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsALEC - ACCESS Newswire
Will Alector Inc. stock split again soonJuly 2025 Gainers & Safe Entry Momentum Stock Tips - Улправда
Is Alector Inc. stock attractive for hedge fundsJuly 2025 Big Picture & AI Optimized Trading Strategy Guides - Улправда
What catalysts could drive Alector Inc. stock higherMarket Growth Review & AI Powered Trade Plan Recommendations - Улправда
Profit Review: How rising interest rates impact Alector Inc. stockShort Setup & Reliable Volume Spike Trade Alerts - Улправда
Alector appoints Neil Berkley as chief financial officer - MSN
Hedge Fund Bets: Can Alector Inc. stock sustain free cash flow growth2025 Stock Rankings & Reliable Entry Point Trade Alerts - Улправда
Will Alector Inc. stock outperform tech sector in 2025CEO Change & Daily Technical Forecast Reports - Улправда
Shareholders that lost money on Alector, Inc.(ALEC) should contact Levi & Korsinsky about Securities Fraud InvestigationALEC - ACCESS Newswire
Will Alector Inc. stock reach Wall Street targetsPortfolio Performance Report & High Conviction Buy Zone Alerts - DonanımHaber
Can Alector Inc. (0Z2) stock deliver strong annual returnsJuly 2025 Drop Watch & Smart Allocation Stock Tips - DonanımHaber
Is Alector Inc. stock a top momentum play2025 Bull vs Bear & Daily Technical Stock Forecast Reports - DonanımHaber
Options Flow: What catalysts could drive Alector Inc. stock higherJuly 2025 Summary & Expert-Curated Trade Recommendations - Улправда
Will Alector Inc. stock reach all time highs in 2025Bond Market & Fast Moving Stock Trade Plans - DonanımHaber
Can Alector Inc. stock sustain free cash flow growthFed Meeting & Free Weekly Watchlist of Top Performers - Улправда
Will Alector Inc. stock deliver long term returnsJuly 2025 Technicals & Low Risk Growth Stock Ideas - Улправда
Alector, Inc.(NasdaqGS: ALEC) dropped from NASDAQ Biotechnology Index - marketscreener.com
Investigation Alert: Alector, Inc. (ALEC) Under ScrutinyContact Levi & Korsinsky For Details - ACCESS Newswire
Alector Earnings Notes - Trefis
Alector Stock Down After Latozinemab Failure, Eyes On Phase 2 Catalyst (ALEC) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Alector (ALEC) and Novan (NOVN) - The Globe and Mail
Alector (ALEC) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Alector Appoints Neil Berkley as CFO - The Globe and Mail
How currency fluctuations impact Alector Inc stockMarket Trend Report & Expert Approved Momentum Trade Ideas - moha.gov.vn
Rate Cut: Is Alector Inc stock a safe investment in uncertain marketsTrade Entry Summary & Smart Swing Trading Techniques - moha.gov.vn
Alector (ALEC) Appoints Neil Berkley as CFO - GuruFocus
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer - The Manila Times
Alector, Inc. Appoints Neil Berkley as Chief Financial Officer - Quiver Quantitative
Alector (NASDAQ: ALEC) appoints Neil Berkley as chief financial officer - Stock Titan
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer | Associated Press | syndication news - Enidnews.com
Alector, Inc. Appoints Neil Berkley as Chief Financial Officer, Effective December 10, 2025 - marketscreener.com
Alector Announces Topline Results from Phase 3 INFRONT-3 Clinical Trial Evaluating Latozinemab - MSN
Alector’s Latozinemab Study: A Promising Continuation for Neurodegenerative Disease Treatment - MSN
Alector principal accounting officer Wong-Sarad sells $5,751 in stock By Investing.com - Investing.com South Africa
Alector principal accounting officer Wong-Sarad sells $5,751 in stock - Investing.com
Transcript : Alector, Inc. Presents at BofA Securities CNS Therapeutics Virtual Conference 2025, Dec-08-2025 02 - marketscreener.com
Performance Recap: What valuation ratios show for Alector Inc 0Z2 stockStock Surge & Fast Entry Momentum Trade Alerts - moha.gov.vn
Alector, Inc. (NASDAQ:ALEC) Receives Average Rating of "Reduce" from Brokerages - MarketBeat
How the Narrative Surrounding Alector Has Changed After the Latozinemab Trial Failure - Yahoo Finance
Alector Inc Stock (ALEC) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):